Brentuximab vedotin
- Generic Name
- Brentuximab vedotin
- Brand Names
- Adcetris
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 914088-09-8
- Unique Ingredient Identifier
- 7XL5ISS668
- Background
Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug labe...
- Indication
Brentuximab vedotin is indicated in adult patients for the treatment of previously untreated stage III or IV classical Hodgkin's lymphoma (cHL) in combination with doxorubicin, vinblastine, and dacarbazine. It is also indicated for the treatment of cHL post-autologous hematopoietic stem cell transplantation (auto-HSCT) in patients at high risk of relapse or ...
- Associated Conditions
- CD30-expressing Mycosis Fungoides (MF), Classical Hodgkin's Lymphoma, Peripheral T-Cell Lymphoma (PTCL), Primary Cutaneous Anaplastic Large Cell Lymphoma, Systemic Anaplastic Large Cell Lymphoma, Stage 3 Classical Hodgkin's Lymphoma
- Associated Therapies
- -
A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma
- First Posted Date
- 2013-11-21
- Last Posted Date
- 2021-04-09
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT01990534
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2013-11-08
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 137
- Registration Number
- NCT01979536
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸Valley Children's Hospital, Madera, California, United States
🇺🇸Naval Medical Center - Portsmouth, Portsmouth, Virginia, United States
A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2013-09-25
- Last Posted Date
- 2016-05-11
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT01950364
Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD)
- First Posted Date
- 2013-09-12
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 19
- Registration Number
- NCT01940796
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)
- Conditions
- Interventions
- First Posted Date
- 2013-08-20
- Last Posted Date
- 2018-06-21
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 87
- Registration Number
- NCT01925612
- Locations
- 🇺🇸
Mid Ohio Oncology/Hematology Inc, Columbus, Ohio, United States
🇺🇸Texas Oncology - Baylor Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Johns Hopkins Medical Center, Baltimore, Maryland, United States
Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2013-08-12
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 77
- Registration Number
- NCT01920932
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸Maine Children's Cancer Program (MCCP), Scarborough, Maine, United States
🇺🇸Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States
Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
- First Posted Date
- 2013-07-29
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Takeda
- Target Recruit Count
- 50
- Registration Number
- NCT01909934
- Locations
- 🇵🇱
Malopolskie Centrum Medyczne s.c., Krakow, Poland
🇵🇱Uniwersyteckie Centrum Kliniczne, Gdansk, Poland
🇧🇪Cliniques Universitaires Saint-Luc, Bruxelles, Belgium
Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2013-07-18
- Last Posted Date
- 2015-11-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 3
- Registration Number
- NCT01902160
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 146
- Registration Number
- NCT01896999
- Locations
- 🇺🇸
Anchorage Oncology Centre, Anchorage, Alaska, United States
🇺🇸Katmai Oncology Group, Anchorage, Alaska, United States
🇺🇸Providence Alaska Medical Center, Anchorage, Alaska, United States
Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma
- First Posted Date
- 2013-06-10
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT01874054
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Saint Francis Hospital / Bon Secours, Greenville, South Carolina, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.